ArticleInternal and emergency medicine2026
Global trends and projections in cardiovascular disease-related heart failure, 1990-2050: an analysis of the Global Burden of Disease 2021 data.
Article in Internal and emergency medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- TriFusion-PCGNet: A Hybrid Multi-Branch Deep Learning Network for Energy-Aware Normal/Abnormal Heart Sound Classification.Life (Basel, Switzerland) · 2026Article
- Self-care profiles and quality of life trajectories in patients with chronic heart failure-caregiver dyads: a prospective cohort study.BMC nursing · 2026Article
- DTF-STCANet: A Dual Time-Frequency Swin Transformer and ConvNeXt Attention Network for Heart Sound Classification.Diagnostics (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Heart failure (HF) is a major endpoint of cardiovascular disease (CVD) and a growing global public health challenge. This study assessed the global burden of CVD-related HF from 1990 to 2021 and projected trends to 2050. Utilizing data from the Global Burden of Disease (GBD) 2021 study, we analyzed years lived with disability (YLD) and prevalence for CVD-related HF, stratified by sex, age, socio-demographic index (SDI), region, and specific CVD etiology. In 2021, CVD-related HF affected approximately 45.56 million individuals globally, causing 4.32 million YLD. The global age-standardized prevalence and YLD rates were 548.81 and 52.00 per 100,000 population, respectively, with higher rates in males. Hypertensive and ischemic heart disease were predominant causes, except in the under-20 age group where cardiomyopathy/myocarditis and rheumatic heart disease prevailed. From 1990 to 2021, global age-standardized prevalence and YLD rates increased, with the sharpest rise in the 20-54 age group, males and middle to high-middle SDI countries. Age-standardized prevalence and YLD rates declined for rheumatic heart disease, stroke, and non-rheumatic valvular heart disease-related HF, whereas most other etiologies exhibited upward trends, most notably atrial fibrillation/flutter and endocarditis. There were significant disparities in various CVD-related HF across sex, age, SDI country, and region in 2021 and from 1990 to 2021. By 2050, projections indicate that CVD-related HF will increase to varying degrees across sex, age, and specific CVD types. The global burden of CVD-related HF is substantial, escalating, and characterized by significant disparities across sex, age, SDI country, region, and CVD type. Urgent and targeted public health strategies are essential to mitigate this rising burden.
Indexed as
Identifiers
41656464What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.